Amarin (AMRN) -6.8% after saying that doesn't expect a decision from the FDA this month on whether to grant the company's request for five-year marketing exclusivity for its Vascepa heart pill, which the agency approved in July. Amarin doesn't haven't a clue whether the FDA will grant its request or when it will make a decision.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Wed, 8:45AM)
at Zacks.com (Mon, 9:13AM)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs